Demonstrates Potential of Hyb & Seq NGS Platform for Infectious Disease Applications
“We’re excited to have the opportunity to showcase the capabilities of our three molecular profiling platforms – nCounter®, GeoMx™ DSP, and Hyb & Seq™ NGS,” said
Introducing Hyb & Seq™ NGS Platform for Infectious Disease Applications
General Hospital and
Scientific Session: A Quantitative, Multiplexed RNA Detection Platform for Rapid Pathogen Identification and Phenotypic Antibiotic Susceptibility Testing (AST) using
Poster: Rapid and Accurate Cross-Kingdom Human Pathogen Identification and Detection using Hyb & Seq™ Technology
Advances in Digital Spatial Profiling with GeoMx™
Poster: Characterization of the Tumor Microenvironment using a
Poster: Validation of antibody panels for high-plex immunohistochemistry applications
nCounter® Analysis System
You can visit
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential of the company’s Hyb and Seq NGS Platform for future clinical applications such as infectious disease. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include product development or clinical studies; market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the
Source: NanoString Technologies, Inc.